Abstract
Neuropeptide Y (NPY), a potent orexigen peptide widely produced and distributed in arcuate neurons in the hypothalamus, is a promising candidate for the control of appetitive ingestive behavior. In mammals, the signaling is mediated via at least five different cell surface receptors, denoted as Y1, Y2, Y4, Y5 and Y6. Obesity is an important public health problem in the world, particularly in developed societies, and has taken on pandemic proportions. The therapeutics of obesity, including appetite suppressants, has increased 453% over the past decade, although issues concerning safety, efficacy, and little knowledge of the pharmacological activity result in the still modest effects of the anti-obesity drugs presently used. Ligands for Y receptors may be of benefit for the treatment of obesity, and recent findings have indicated a promising role of Y2 and Y4 in protecting against diet-induced obesity. This review highlights the supporting evidence therapeutic potential of Y2 and Y4 receptors antagonists as additional intervention to treat human obesity.
Keywords: Appetite Regulation, Body Weight, Food Intake, Neuropeptide Y, Neuropeptide Y Receptors, Obesity
Current Topics in Medicinal Chemistry
Title: NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Volume: 7 Issue: 17
Author(s): M. M. Kamiji and A. Inui
Affiliation:
Keywords: Appetite Regulation, Body Weight, Food Intake, Neuropeptide Y, Neuropeptide Y Receptors, Obesity
Abstract: Neuropeptide Y (NPY), a potent orexigen peptide widely produced and distributed in arcuate neurons in the hypothalamus, is a promising candidate for the control of appetitive ingestive behavior. In mammals, the signaling is mediated via at least five different cell surface receptors, denoted as Y1, Y2, Y4, Y5 and Y6. Obesity is an important public health problem in the world, particularly in developed societies, and has taken on pandemic proportions. The therapeutics of obesity, including appetite suppressants, has increased 453% over the past decade, although issues concerning safety, efficacy, and little knowledge of the pharmacological activity result in the still modest effects of the anti-obesity drugs presently used. Ligands for Y receptors may be of benefit for the treatment of obesity, and recent findings have indicated a promising role of Y2 and Y4 in protecting against diet-induced obesity. This review highlights the supporting evidence therapeutic potential of Y2 and Y4 receptors antagonists as additional intervention to treat human obesity.
Export Options
About this article
Cite this article as:
Kamiji M. M. and Inui A., NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?, Current Topics in Medicinal Chemistry 2007; 7 (17) . https://dx.doi.org/10.2174/156802607782340957
DOI https://dx.doi.org/10.2174/156802607782340957 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Different Treatment Strategies for Pediatric Brain Tumors
Current Pediatric Reviews Tissue Engineering Applications and Stem Cell Approaches to the Skin, Nerves and Blood Vessels
Current Stem Cell Research & Therapy Factors Modulating Chondrogenesis and Mechano-Inductive Systems for Cartilage Tissue Engineering from Mesenchymal Stem Cells: A Review
Current Tissue Engineering (Discontinued) CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Exercise Preconditioning Reduces Brain Damage and Inhibits TNF-α Receptor Expression after Hypoxia/Reoxygenation: An In Vivo and In Vitro Study
Current Neurovascular Research Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Current Gene Therapy Modulation of Aquaporins by Dietary Patterns and Plant Bioactive Compounds
Current Medicinal Chemistry Substance P: Structure, Function, and Therapeutics
Current Topics in Medicinal Chemistry Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Comparison of Isolation, Expansion and Cryopreservation Techniques to Produce Stem Cells from Human Exfoliated Deciduous Teeth (SHED) with Better Regenerative Potential
Current Stem Cell Research & Therapy The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology